US Patent

US8512745 — Ulipristal acetate tablets

Formulation · Assigned to Laboratoire HRA Pharma SAS · Expires 2030-06-02 · 4y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a pharmaceutical tablet formulation of ulipristal acetate with specific excipients in certain weight percentages for oral administration.

USPTO Abstract

The invention relates to a pharmaceutical tablet for oral administration comprising ulipristal acetate together with the following excipients: a diluent in an amount of 60 to 95 wt %, a binding agent in an amount of 1 to 10 wt %, croscarmellose sodium in an amount of 1 to 10 wt %, and magnesium stearate in an amount of 0 to 5 wt %.

Drugs covered by this patent

ulipristal-acetate (ULIPRISTAL ACETATE)

Patent Metadata

Patent number: US8512745
Jurisdiction: US
Classification: Formulation
Expires: 2030-06-02
Drug substance claim: No
Drug product claim: Yes
Assignee: Laboratoire HRA Pharma SAS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.